NCT06309394View on ClinicalTrials.gov

A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]INCB099280 in Healthy Male Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

5

Participants

Timeline

Start Date

May 15, 2024

Primary Completion Date

June 4, 2024

Study Completion Date

June 4, 2024

Conditions

Healthy Participants

Interventions

DRUG

INCB099280

INCB099280 will be administered orally, followed approximately 10 minutes later by an oral dose solution of radiolabeled INCB099280.

Trial Locations (1)

NG11 6JS

Quotient Sciences Ltd, Nottingham

Sponsors

Lead Sponsor

Incyte Corporation

All Listed Sponsors

lead

Incyte Corporation

INDUSTRY

NCT06309394 - A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]INCB099280 in Healthy Male Participants | Biotech Hunter | Biotech Hunter